Schizophrenia Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Schizophrenia stocks.

Schizophrenia Stocks Recent News

Date Stock Title
May 28 BLRX BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript
May 28 BMY ASPIRE: Our Commitment To Address Health Inequities in Low- and Middle-Income Countries
May 28 RVPH Reviva Pharmaceuticals looks to raise $3M through direct offering; shares fall
May 28 RVPH Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
May 28 BLRX biolinerx GAAP EPS of $0.00 beats by $0.29, revenue of $6.86M beats by $6.52M
May 28 ALKS Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024
May 28 BLRX BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
May 25 BMY Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo
May 24 NERV Candel Reports Upbeat Data From Lung Cancer Study
May 24 BLRX biolinerx Q1 Earnings Preview
May 24 ACAD After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
May 24 INDV With 59% ownership, Indivior PLC (LON:INDV) boasts of strong institutional backing
May 24 BMY Terran Biosciences prepares for trials of schizophrenia drug
May 24 BLRX BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
May 23 BMY Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms
May 23 BMY Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity
May 23 BMY Does Bristol-Myers Squibb (NYSE:BMY) Have A Healthy Balance Sheet?
May 23 BMY This Unpopular Dividend Stock Is a Buy
May 23 INDV Indivior to Host Analyst Teach-in Event in New York City; Reconfirms Full Year 2024 Guidance
May 23 BMY Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
Schizophrenia

Schizophrenia is a mental disorder characterized by abnormal behavior, strange speech and a decreased ability to understand reality. Other symptoms include false beliefs, unclear or confused thinking, hearing voices that do not exist, reduced social engagement and emotional expression and lack of motivation. People with schizophrenia often have additional mental health problems such as anxiety, depressive or substance-use disorders. Symptoms typically come on gradually, begin in young adulthood and in many cases never resolve.The causes of schizophrenia include environmental and genetic factors. Possible environmental factors include being raised in a city, cannabis use during adolescence, certain infections, the age of a person's parents, and poor nutrition during pregnancy. Genetic factors include a variety of common and rare genetic variants. Diagnosis is based on observed behavior, the person's reported experiences and reports of others familiar with the person. During diagnosis, a person's culture must also be taken into account. As of 2013, there is no objective test. Schizophrenia does not imply a "split personality" or dissociative identity disorder, conditions with which it is often confused in public perception.The mainstay of treatment is antipsychotic medication, along with counselling, job training and social rehabilitation. It is unclear whether typical or atypical antipsychotics are better. In those who do not improve with other antipsychotics, clozapine may be tried. In more serious situations where there is risk to self or others, involuntary hospitalization may be necessary, although hospital stays are now shorter and less frequent than they once were.About 0.3% to 0.7% of people are affected by schizophrenia during their lifetimes. In 2013, there were an estimated 23.6 million cases globally. Males are more often affected and on average experience more severe symptoms. About 20% of people eventually do well, and a few recover completely; about 50% have lifelong impairment. Social problems, such as long-term unemployment, poverty and homelessness, are common. The average life expectancy of people with the disorder is 10–25 years less than that of the general population. This is the result of increased physical health problems and a higher suicide rate (about 5%). In 2015, an estimated 17,000 people worldwide died from behavior related to, or caused by, schizophrenia.

Browse All Tags